Hemab Therapeutics (COAG) Stock Price & Analysis

COAG$34.81—
BiotechnologyValue StockGrowth Stock
Compare
Market cap$1.91BEnterprise value$1.39BRevenue (TTM)$0Market position—

Score

70
Bullish
Value
66
Quality
50
Growth
95

AI Analysis

Snapshot

Hemab Therapeutics Holdings, Inc. Common Stock is a growth-led story right now — Growth 95/100 is the pillar doing the heavy lifting (overall 70/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~48% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

66
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

95
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

50
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) last printed $34.81. Equity value is $1.91B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2025
$0.00

About

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.

Hemab Therapeutics (COAG) Stock Price & Analysis

COAG price $34.81 —

Ticker
COAG
Price
$34.81
Change
—
Market cap
$1.91B
Dividend yield
0.00%
Beta
1.85
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
70
Value
66
Quality
50
Growth
95

Stocklytics score rationale: value 66, quality 50, growth 95.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener